Introduction
The immune system has the task of defending the body from infections caused by a variety of microorganisms foreign to the body. Vaccines were and are made to boost the immune response against a given bacteria, virus, or harmful toxins generated by microorganisms. While the body has an armamentarium in terms of cells and molecules endowed with the property of responding and reacting with various "invaders", the process to build up adequate immunity takes time. Vaccination with a killed or attenuated microbe performs this function and builds up adequate immunity against an eventual infection. Interestingly, some vaccines also have therapeutic properties.
This communication describes briefly the making of an immunoprophylactic-cumimmunotherapeutic vaccine initially developed against leprosy. The vaccine has received the approval of the Drugs Controller General of India (DCGI) and also of the US Food and Drug Administration (FDA). It is at present the only vaccine of its type in the world. It has been taken up by the industry and is available to the public. Besides leprosy, it has found therapeutic utility in the treatment of category II ("difficult to treat") tuberculosis. Astonishingly, it cures ugly anogenital warts, presumably by potentiating both cellular and humoral immune responses. Its efficacy in prevention and treatment of SP2/O myeloma in mice has also been reported. It is employed as an adjuvant in a potential birth control vaccine against human chorionic gonadotropin (hCG) for preventing pregnancy.
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Talwar et al tried. His thesis is one of the shortest on record. The majority (~99%) of humans can resist infection of M. leprae successfully, and do not become leprosy patients. The few who become victim to the disease manifest a spectrum ranging from a single lesion with few if any bacteria, classified as tuberculoid (TT) to multibacillary lepromatous leprosy (LL) with multiple lesions loaded with M. leprae. This spectrum is a reflection of the existence of complete or variable degrees of immune response against M. leprae in patients manifesting the different forms of leprosy. Our first task was to learn of what goes wrong or is deficient in humans who become victims of the disease. After learning this, the next task obviously was to see whether anything can be done to prevent humans contracting the disease.
Nature of immune deficit in leprosy
Those who contract leprosy have T cells that are unable to react against some key antigen(s) of M. leprae. Their immune system is otherwise fairly normal, and they respond normally to cholera or typhoid vaccines.
1 T lymphocytes generate the signal for macrophages to prevent the proliferation of phagocytosed M. leprae. Table 1 gives data clearly supporting the role of T cells in this process. In this experiment, monocyte-derived macrophages from either TT leprosy patients or those suffering from the LL form of the disease were infected with M. leprae derived from patients. Radioactive thymidine ( 3 H-thymidine) was used as a precursor in the medium. It was incorporated into DNA by M. leprae engulfed in macrophages derived from either LL or TT leprosy patients. However, if T cells derived from TT patients were also included in culture, the incorporation of 3 H-thymidine by M. leprae was restricted, whereas T lymphocytes derived from LL patients lacked this property. 
Can anything be done to restore this deficiency?
This was the basic requirement of an eventual vaccine against leprosy. Vaccines are usually made using the killed or attenuated forms of infecting microorganisms. Such a homologous approach was illogical for leprosy, as the basic defect in LL patients is their inability to respond to key antigen(s) of M. leprae. Therefore, a heterologous approach was adopted.
Search for an atypical
Mycobacterium sharing antigens with M. leprae Whereas M. leprae is noncultivable, a candidate for a vaccine against leprosy has to be cultivable in one medium or another to enable its production on a large scale for public use. We collected 16 cultivable, atypical mycobacteria from various sources, some already named and classified, others lying in various atypical collections. Each of them was coded and investigated for its ability to cause blast transformation of T cells from not only TT but also LL patients. 3 Their ability to generate cytokines influencing macrophage function was investigated. 4 The ensemble of these investigations led to the shortening of the list of 16 to 5 mycobacteria. These were M. vaccae, M. phlei, M. gordonae, ICRC bacillus, and Mycobacterium w (Mw).
To confirm their closeness to M. leprae, lepromin-like preparations were made of these five atypical mycobacteria and evaluated alongside lepromin prepared from M. leprae in TT and LL patients to evoke M. leprae lepromin-like responses in leprosy patients. An atypical mycobacteria (Mw) appeared to possess these molecular traits. 5 Could Mw serve as a vaccine? Can it convert leprominnegative leprosy patients to lepromin-positive status? This investigation was carried by Chaudhary et al at the School of Tropical Medicine, Kolkata. Twenty of 32 leprosy patients who were consistently lepromin negative were converted from lepromin-negative to leprominpositive status after a single intradermal injection of autoclaved Mw. 6 This was confirmed by Kar et al 7 in lepromin-negative family members and contacts of leprosy patients in Delhi. A total of 67 of 68 (98.5%) converted 
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Prophylactic/therapeutic vaccine for leprosy to lepromin-positive status after two immunizations with Mw. These observations pointed out the potential of Mw to serve as an immunoprophylactic vaccine to protect susceptible family members from contracting leprosy on continuous exposure to M. leprae from a multibacillary leprosy patient.
Therapeutic action of Mw
Zaheer et al administered autoclaved Mw as adjunct to standard multidrug therapy (MDT) to treat multibacillary leprosy patients. A parallel group received a tenth of the dose of tetanus toxoid as adjunct. It was observed that the inclusion of Mw with the drugs expedited bacterial clearance and shortened the period of complete recovery.
8 Figure 1 illustrates the remarkable property of Mw in not only expediting recovery but also clearing granulomas in patients.
9
Efficacy in slow responders
Fourteen patients who were not responding adequately to standard treatment with MDT were referred to our treatment center. They were randomly distributed into two groups: one group continued to receive MDT, and the second group was also given MDT with Mw vaccine as an adjunct. Figure 2 shows the dynamics of bacterial index values in two of these patients. Soon after immunization with Mw, the bacterial index started declining noticeably, followed by full recovery of the patients. 10 This was not the case in the group receiving drugs alone, in whom the decline continued to be extremely slow ( Figure 3 ). 
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Conversion of borderline leprosy/LL patients to lepromin-positive status by Mw
LL patients are all lepromin negative, one of the criteria employed for classifying the patient in this category, and they continue to be lepromin negative even after bacterial clearance is achieved with drugs. Drugs kill the bacteria but do not improve the immune response. It was pertinent to examine whether the inclusion of Mw for treatment had any effect on the delayed skin-hypersensitivity response to M. leprae, manifested as a positive response to lepromin. Figure 4 shows the dynamics of the conversion of patients from lepromin-negative to lepromin-positive status.
Clearance of bacilli from peripheral nerves
M. leprae infects the peripheral nerve cells, causing loss of sensitivity. Zaheer et al 10 had the good idea to investigate whether inclusive treatment with Mw in patients eliminated fully or partially the bacilli infecting the nerve cells. Table 2 gives the observations. In contrast to drugs alone, where bacilli persisted in peripheral nerves of some patients, in the group receiving Mw, bacilli were eliminated in the peripheral nerves of all patients investigated.
Approval by drug regulatory authorities
Phase-wise clinical trials were conducted with due approval of ethics committees and drug regulatory authorities in recognized centers, followed by field trials in Kanpur Dehat in 272 villages inhabited by 420,823 people. Kanpur Dehat used to be one of the endemic districts for leprosy. Patients suffering from leprosy were treated with drugs and the Mw vaccine. Their household contacts who had been exposed received the vaccine based on Mw in the hope that they would 
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Prophylactic/therapeutic vaccine for leprosy be protected from becoming patients. Observations made during these trials are reported elsewhere. 11, 12 Vaccination with Mw shortened treatment time of patients. In addition, no side effects of any significance were seen by vaccination of healthy contacts with Mw. Our vaccine has received the approval of the DCGI and was licensed to a company to enable its availability to the public. In due course, it also received the approval of the FDA.
Move for eradication of leprosy
Eradication of small pox was achieved by planned use of a vaccine against that infectious disease. An Indian government committee led by Soumya Swaminathan, Director-general of the Indian Council of Medical Research, has decided to evaluate the use of M. indicus pranii (MIP) to eliminate if not eradicate leprosy in India. To begin with, a field project will be launched in five districts of high endemism in the country. The index patient will receive the vaccine in addition to MDT. Their family members and contacts will be immunized with the MIP vaccine twice at 6-month intervals with the hope that they will not become patients.
Tuberculosis
The company licensed to manufacture Mw vaccine asked from us a biological test to confirm that they were growing the right bacteria. As Mw shares antigens with M. tuberculosis besides M. leprae, we thought of testing whether Mw could prevent tuberculosis in guinea pigs following infection with the pathogenic strain M. tuberculosis H 37 R V . This was indeed the case. As shown in Figure 5 , after 3 weeks the lungs had nodules full of M. tuberculosis and the spleen was enlarged. Immunization with Mw prevented these from happening. 
Similarities and differential properties of Mw with respect to BCG
Bacillus Calmette-Guérin (BCG) is effective only in live form and loses immunizing capability in a dead state, whereas Mw is effective in both live and in autoclaved form. Furthermore, in contrast to BCG, Mw seems to have no genetic restrictions. As shown in Figure 6 , Mw prevented the growth of pulmonary lesions in all four genetic strains (C3H, CBA, BALB/c, C57BL) of mice investigated, whereas BCG was effective in BALB/c and C57BL but not in CBA or C3H mice. 13 
Treatment of category II tuberculosis patients
Mw was employed as adjunct for treatment of category II (difficult to treat) tuberculosis patients in an exploratory trial conducted in Ahmedabad. Table 3 gives the results. Inclusion of Mw with drugs improved recovery considerably. What is further significant is that patients receiving Mw with drugs had much lower relapse rates (Figure 7 ).
Gene sequencing of Mw
Reddi et al carried out a molecular analysis of Mw, which indicated it as a unique species.
14 Three recognized centers were given a grant by the Department of Biotechnology, Government of India to determine the genome sequence and carry out molecular definition of Mw, an atypical cultivable mycobacterium with remarkable therapeutic traits of relieving leprosy and tuberculosis. Their findings are reported 
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Prophylactic/therapeutic vaccine for leprosy elsewhere. 15 Mw was considered an ancestor of both M. leprae and M. tuberculosis. No bacteria of this definition had heretofore existed in the International Depository. It was named Mycobacterium indicus pranii (MIP). 16 
Unexpected astonishing properties of MIP
Every now and then, SG at the All India Institute of Medical Sciences receives patients harboring ugly anogenital warts. He found that administration of MIP caused remarkable recovery of these warts. Figure 8 shows the clearance of the warts. Figure 9 shows an ugly lesion on the anus. Among the first nine patients suffering from such anogenital warts, three were positive for HIV. In spite of that, they benefited from this treatment. These observations have been published elsewhere. 17 Similar warts occurring elsewhere in the body were also healed ( Figure 10 ).
18
Prevention and therapy of SP2/O myelomas in mice
Rakshit et al showed the prevention and anticancerous action of MIP on development of SP2/O myelomas in BALB/c mice.
19 Figure 11 gives a summary of their findings. They have also reported the generation by MIP of cytokines IL-2 and IFNγ, which may be involved in this action.
Potent adjuvant properties of
Mycobacterium indicus pranii
Our laboratory is involved in making a recombinant vaccine against hCG, which has the potential of preventing pregnancy in sexually active women without derangement of ovulation and menstrual regularity. Inclusion of MIP as an adjuvant in the vaccine enhances antibody titers remarkably ( Figure 12 ). MIP is a potent invigorator of immune response. MIP given as an adjunct to standard MDT expedites bacterial clearance and shortens the period of complete recovery of leprosy patients. It also upgrades the immune response of patients to M. leprae, which is not achieved 
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Prophylactic/therapeutic vaccine for leprosy by drugs. MIP has received the approval of the DCGI and the FDA. Besides leprosy, it has been used successfully as an adjunct in the treatment of category II (difficult to treat) tuberculosis patients. MIP appears to be a potent invigorator of both humoral and cellular immune responses. Used as an adjuvant, it enhances considerably the antibody response to the hCGβ-LTB vaccine, under development for control of fertility. Given intralesionally, it cures ugly anogenital warts. It suppresses growth of SP2/O myeloma tumors in BALB/c mice, presumably by inducing T-helper 1 cytokines.
